Victory Capital Management Inc. Buys 77,874 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

Key Points

• Victory Capital Management Inc. increased its stake in ADMA Biologics by 70.8%, now holding 187,822 shares valued at approximately $3.7 million.
• Less than 4% of ADMA Biologics' stock is owned by company insiders, who have sold a total of 464,621 shares recently, including significant sales by Directors Steve Elms and Lawrence P. Guiheen.
• ADMA Biologics reported a quarterly revenue of $114.8 million, missing estimates, but showing a 40.2% year-over-year increase in revenue.

Victory Capital Management Inc. raised its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 70.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 187,822 shares of the biotechnology company's stock after acquiring an additional 77,874 shares during the quarter. Victory Capital Management Inc. owned about 0.08% of ADMA Biologics worth $3,726,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Tsfg LLC bought a new position in shares of ADMA Biologics in the 1st quarter worth about $51,000. Farther Finance Advisors LLC increased its holdings in ADMA Biologics by 1,149.1% in the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 2,505 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in ADMA Biologics in the fourth quarter worth approximately $85,000. CIBC Private Wealth Group LLC increased its holdings in ADMA Biologics by 137.1% in the fourth quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock worth $95,000 after purchasing an additional 2,954 shares in the last quarter. Finally, Covestor Ltd increased its holdings in ADMA Biologics by 7,038.1% in the fourth quarter. Covestor Ltd now owns 5,996 shares of the biotechnology company's stock worth $103,000 after purchasing an additional 5,912 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Jerrold B. Grossman sold 10,000 shares of ADMA Biologics stock in a transaction on Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the sale, the director directly owned 478,194 shares in the company, valued at approximately $10,190,314.14. This trade represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Steve Elms sold 194,749 shares of ADMA Biologics stock in a transaction on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the sale, the director owned 87,330 shares in the company, valued at $1,767,559.20. This trade represents a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 464,621 shares of company stock worth $9,644,269. 3.50% of the stock is owned by corporate insiders.

ADMA Biologics Stock Up 1.1%

Shares of NASDAQ ADMA traded up $0.20 during midday trading on Thursday, hitting $18.79. 366,042 shares of the stock traded hands, compared to its average volume of 3,057,510. The company has a market cap of $4.48 billion, a PE ratio of 22.06 and a beta of 0.43. ADMA Biologics Inc has a one year low of $10.21 and a one year high of $25.67. The business has a 50 day moving average price of $18.86 and a two-hundred day moving average price of $18.72. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The company had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. During the same quarter last year, the company posted $0.08 EPS. The company's quarterly revenue was up 40.2% compared to the same quarter last year. On average, equities analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Wall Street Zen cut ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James Financial boosted their price objective on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.